Clinical Trials Browser

INDUSTRY × Interventional × Axitinib × Clear all

NCT07227415 2026-05-22

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

Phase 1/2 Recruiting

Clear-cell metastatic renal cell carcinoma, Carcinoma, Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis

NCT05805501 2026-05-12

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

Phase 2 Active not recruiting

Carcinoma, Renal Cell

NCT05059522 2026-04-14

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Phase 3 Active not recruiting

Ovarian Neoplasms

NCT05017012 2026-03-27

MK-3475A-C18

Phase 1 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT02853331 2026-02-02

KEYNOTE-426

Phase 3 Completed

861 enrolled 24 charts 1 FDA

Carcinoma, Renal Cell

NCT04585815 2026-01-09

Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

Phase 1/2 Terminated

34 enrolled 44 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT06962787 2025-11-17

A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer

Phase 2 Recruiting

Kidney Neoplasms

NCT04458259 2025-08-28

Study of PF-07265807 in Participants With Metastatic Solid Tumors.

Phase 1 Terminated

DermatologicGastrointestinalGenitourinaryGynecologicThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Small Cell Lung Carcinoma

NCT05949632 2025-08-03

A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors

Phase 1/2 Terminated

GynecologicSarcoma

Adenocarcinoma, Mucinous, Carcinosarcoma, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Uterine Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Cystadenocarcinoma, Serous

NCT02684006 2025-07-30

JAVELIN Renal 101

Phase 3 Completed

886 enrolled 37 charts 1 FDA

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms

NCT04522323 2025-07-25

A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma

Phase 1 Active not recruiting

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Renal Cell

NCT05256472 2025-03-06

A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma

Phase 2 Active not recruiting

Carcinoma, Renal Cell

NCT05097599 2025-01-08

StrataPATH

Phase 2 Terminated

Neoplasms

NCT00828919 2024-12-03

Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials

Phase NA Completed

52 enrolled 12 charts

Other solid neoplasm

Solid Tumors

NCT02639182 2024-11-18

A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma

Phase 2 Completed

133 enrolled 35 charts

Carcinoma, Renal Cell

NCT02667886 2024-10-03

Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma

Phase 1/2 Completed

74 enrolled 20 charts

Carcinoma, Renal Cell

NCT05420220 2024-05-01

Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer

Phase 2 Recruiting

Advanced Non-small Cell Lung Cancer

NCT03472560 2024-04-09

A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)

Phase 2 Terminated

61 enrolled 26 charts

GenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT04540705 2024-02-28

PIVOT IO 011

Phase 1 Completed

Carcinoma, Renal Cell

NCT00920816 2022-05-06

Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer

Phase 3 Completed

492 enrolled 17 charts

Kidney Neoplasms

NCT02493751 2022-02-18

JAVELIN Renal 100

Phase 1 Completed

55 enrolled 27 charts

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms

NCT02133742 2021-07-28

A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer

Phase 1 Completed

52 enrolled 27 charts

Carcinoma, Renal Cell

NCT01806064 2020-10-19

Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma

Phase 1/2 Terminated

173 enrolled 17 charts

Carcinoma, Renal Cell

NCT01999972 2020-09-24

A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors

Phase 1 Completed

50 enrolled 29 charts

Carcinoma

NCT03289533 2020-09-04

A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)

Phase 1 Completed

22 enrolled 25 charts

Gastrointestinal

Carcinoma, Hepatocellular, Liver Diseases, Neoplasms

NCT02187302 2020-05-28

CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)

Phase 2 Completed

Carcinoma, Renal Cell

NCT01599754 2019-09-20

ATLAS

Phase 3 Terminated

724 enrolled 17 charts

Carcinoma, Renal Cell

NCT00569946 2019-06-05

Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)

Phase 2 Completed

64 enrolled 17 charts

Carcinoma, Renal Cell

NCT00219557 2019-05-14

AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer

Phase 2 Completed

111 enrolled 20 charts

Gastrointestinal

Pancreatic Neoplasms

NCT00678392 2019-01-09

Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer

Phase 3 Completed

723 enrolled 15 charts

Kidney Neoplasms

NCT01210495 2019-01-09

Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma

Phase 2 Completed

224 enrolled 35 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT01441414 2019-01-08

PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma

Phase 2 Terminated

18 enrolled 10 charts

Carcinoma, Renal Cell

NCT00835978 2017-05-30

Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer

Phase 2 Completed

213 enrolled 29 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00768755 2015-10-28

Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer

Phase 1/2 Completed

180 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung

NCT00460603 2013-12-06

Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer

Phase 1/2 Completed

187 enrolled 47 charts

Gastrointestinal

Colorectal Neoplasms

NCT00842244 2013-11-27

Study Of Axitinib In Combination With Cisplatin And Capecitabine In Patients With Advanced Gastric Cancer

Phase 1 Completed

22 enrolled 20 charts

Gastrointestinal

Stomach Neoplasms

NCT00389441 2013-11-25

Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer

Phase 2 Completed

52 enrolled 9 charts

Carcinoma, Thyroid Neoplasms

NCT00600821 2013-11-08

A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.

Phase 2 Completed

118 enrolled 12 charts

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT00615056 2013-04-19

A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen

Phase 2 Completed

171 enrolled 13 charts

Gastrointestinal

Colorectal Neoplasms

NCT00735904 2013-01-03

Trial Of AG-013736, Cisplatin, And Gemcitabine For Patients With Squamous Non-Small Cell Lung Cancer

Phase 2 Completed

38 enrolled 9 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00386555 2012-08-09

A Phase 2 Study in Patients With Advanced Non-Small Cell Lung Cancer Using New Agents With and Without Docetaxel.

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT00282048 2012-07-31

Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer

Phase 2 Completed

62 enrolled 12 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00471146 2012-07-16

Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.

Phase 3 Completed

630 enrolled 13 charts

Gastrointestinal

Carcinoma, Pancreatic Ductal

NCT00076024 2012-06-26

AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer

Phase 1/2 Completed

174 enrolled 14 charts

Breast Neoplasms

NCT00094055 2012-06-26

Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer

Phase 2 Completed

60 enrolled 9 charts

Thyroid Neoplasms

NCT00094094 2012-06-26

Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer

Phase 2 Completed

32 enrolled 9 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00094107 2012-06-26

Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma

Phase 2 Completed

32 enrolled 9 charts

Melanoma, Skin Neoplasms

NCT00071006 2012-06-08

AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)

Phase 2 Completed

12 enrolled 5 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT00447005 2012-05-23

Study Of AG-013736 (Axitinib) In Patients With Advanced Solid Tumors

Phase 1 Completed

12 enrolled 16 charts

Carcinoma

NCT00726752 2012-05-23

A Study In Patients With Advanced Solid Tumor

Phase 1 Completed

6 enrolled 16 charts

Neoplasms